Exploration on 2D DOA Estimation of Linear Array Motion:Uniform Linear Motion

Generally,due to the limitation of the dimension of the array aperture,linear arrays cannot achieve two-dimensional(2D)direction of arrival(DOA)estimation.But the emergence of array motion provides a chance for that.In this paper,a generalized motion scheme and a novel method of 2D DOA estimation are proposed by exploring the linear array motion.To be specific,the linear arrays are controlled to move along an arbitrary direction at a constant velocity and snap per fixed time delay.All the received signals are processed to synthesize the comprehensive observation vector for an extended 2D virtual aperture.Subsequently,since most of 2D DOA estimation methods are not universal to our proposed motion scheme and the reduced-dimensional(RD)method fails to handle the case of the coupled parameters,a decoupled reduced-complexity multiple signals classification(DRC MUSIC)algorithm is designed specifically.Simulation results demonstrate that:a)our proposed scheme can achieve underdetermined 2D DOA estimation just by the linear arrays;b)our designed DRC MUSIC algorithm has the good properties of high accuracy and low complexity;c)our proposed motion scheme with the DRC method has better universality in the motion direction.

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Chimeric antigen receptor T cell(CAR T)therapies have achieved unprecedented efficacy in B-cell tumors,prompting scientists and doctors to exploit this strategy to treat other tumor types.Acute myeloid leukemia(AML)is a group of heterogeneous myeloid malignancies.Relapse remains the main cause of treatment failure,especially for patients with intermediate or high risk stratification.Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect,which unfortunately puts the patient at risk of serious complications,such as graft-versus-host disease.Although the identification of an ideal target antigen for AML is challenging,CAR T therapy remains a highly promising strategy for AML patients,particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease.In this review,we focus on the most recent and promising advances in CAR T therapies for AML.